ライフサイエンスコーパス: dream

1 DP), retinoblastoma (RB)-like, E2F and MuvB (DREAM).

2 is downregulated by p53 independent of LIN37/DREAM.

3 are promising materials for fulfilling this dream.

4 cleavage of HRK's transcriptional repressor DREAM.

5 ll as realization of our "one drug fits all" dream.

6 ed response compared to when they reported a dream.

7 ir release in the human body has long been a dream.

8 role in our ability to remember, imagine and dream.

9 e but also to rapid eye movement (REM) sleep dreams.

10 vening wakefulness, experience more anger in dreams.

11 nia symptoms and trouble sleeping due to bad dreams.

12 n and provide novel insights into memory and dreams.

13 scle paralysis, and is associated with vivid dreams.

14 nisms enabling higher-order consciousness in dreams.

15 e pronounced in lucid compared with nonlucid dreams.

16 ity and induces self-reflective awareness in dreams.

17 nding the neural basis of self-experience in dreams.

18 d to a questionnaire on bodily sensations in dreams.

19 ) strong affective states, such as anger, in dreams.

20 elated to affective experiences in REM sleep dreams.

21 not only during wakefulness but also during dreaming.

22 ol REM sleep, the brain state that underlies dreaming.

23 demonstrated by sleep states associated with dreaming.

24 al hippocampal damage and amnesia engaged in dreaming.

25 ement and bodily sensations during REM sleep dreaming.

26 hat are the properties of consciousness in a dream?

27 How does the brain control dreams?

28 Our findings show that implantation of the DREAMS 2G device in de-novo coronary lesions is feasible

29 tion drug-eluting absorbable metal scaffold (DREAMS 2G) in patients with de-novo coronary artery lesi

30 (4 [10%] vs 2 [5%]), nightmares or abnormal dreams (4 [10%] vs none), upper respiratory tract infect

31 In these studies, mepolizumab ( DREAM: 75 mg, 250 mg, or 750 mg intravenously; MENSA: 75

32 Reverse Engineering Assessments and Methods (DREAM 8) subchallenge: time course prediction in breast

33 ata and on synthetic tumors in the ICGC-TCGA DREAM 8.5 Somatic Mutation Calling Challenge primarily b

34 Reverse Engineering Assessments and Methods (DREAM) 8 Whole-Cell Parameter Estimation Challenge to de

35 ort the results and insights gained from the DREAM 9 Acute Myeloid Prediction Outcome Prediction Chal

36 eam regulatory element antagonist modulator (DREAM), a multifunctional Ca2+-binding protein, is reduc

37 eam regulatory element antagonist modulator (DREAM), a transcriptional repressor, is known to modulat

38 ts completed a questionnaire assessing lucid dreaming ability, and underwent structural and functiona

39 functional colloidal nanoparticles have been dreamed about by scientists and engineers for decades.

40 induced DREAM haplodeficiency or blockade of DREAM activity by chronic administration of the drug rep

41 gene repression during mid to late G1 while DREAM activity was more prominent during G0 and early G1

42 they provided a dream report and rated their dream affect.

43 e know little about the neural correlates of dream affect.

44 logical correlates of sleep stages, and thus dreaming, allow a better understanding of the possibilit

45 However, dreaming also occurs in non-REM (NREM) sleep, characteri

46 hod in recent crowdsourcing benchmark study, DREAM Alzheimer's Disease Big Data challenge to predict

47 The method was submitted to the DREAM Amyotrophic Lateral Sclerosis (ALS) Stratification

48 uction from the off-treatment period between DREAM and COLUMBA.

49 IN52, a key adapter for assembly of both the DREAM and MMB complexes, by a mechanism that requires S2

50 Taken together, we show that DREAM and RB are key factors in the p53 signaling pathwa

51 knockout of RB alone, indicating a role for DREAM and RB in repression of cell cycle genes.

52 tection was linked to an interaction between DREAM and the unfolded protein response (UPR) sensor act

53 s reveal shared neural systems between lucid dreaming and metacognitive function, in particular in th

54 ships between the neural correlates of lucid dreaming and thought monitoring.

55 understanding of the neural underpinnings of dreams and conscious experiences.

56 icline-alone group experienced more abnormal dreams and headaches.

57 characterised by complex motor enactment of dreams and is a potential prodromal marker of Parkinson'

58 hen awakened from sleep, we sometimes recall dreams and sometimes recall no experiences.

59 ata demonstrates specific roles for RB, p130-DREAM, and p107-DREAM in p53 and p21 mediated repression

60 of at least 32 weeks duration (NCT01000506 [DREAM] and NCT01691521 [MENSA]) done between 2009 and 20

61 ng resting wakefulness, predicted ratings of dream anger.

62 both hematopoietic and nonhematopoietic cell DREAMs are required for platelet thrombus formation foll

63 and cell cycle entry and supports a role for DREAM as a therapeutic target in cancer.

64 on, we investigated the structural basis for DREAM assembly.

65 Here, we present our method for DREAM AstraZeneca-Sanger Drug Combination Prediction Cha

66 However, the link to lucid dreaming at the neural level has not yet been explored.

67 unoprecipitation studies for TP53, RB1, E2F, DREAM, B-MYB, FOXM1 and MuvB.

68 Although both RB and DREAM bind and repress an overlapping set of E2F-depende

69 dE2F2/dREAM binding sites are enriched at divergently transcri

70 m regulatory element antagonistic modulator (DREAM) binds to regulatory element sites called DRE in t

71 d in DREAM KO control mice, but not in WT or DREAM bone marrow chimeric mice.

72 nt, while the former may account for why the dreaming brain may undergo executive disconnection and r

73 ction case-studies, including the recent HPN-DREAM breast cancer challenge.

74 egulation of these genes through the p53-p21-DREAM-CDE/CHR pathway appears to be a principal mechanis

75 are expected to be regulated by the p53-p21-DREAM-CDE/CHR pathway.

76 enes through the recently discovered p53-p21-DREAM-CDE/CHR pathway.

77 by extensive simulation studies based on the DREAM challenge benchmark data.

78 he three top-performing methods from the DMI DREAM Challenge for the bioinformatics community.

79 nducted three additional analyses beyond the DREAM challenge question to improve the clinical contrib

80 cterized cancer cell lines, and results of a DREAM Challenge to evaluate computational strategies for

81 we report the results from a community-based DREAM challenge to predict toxicities of environmental c

82 hed the 'Disease Module Identification (DMI) DREAM Challenge', a community effort to build and evalua

83 launched the 'Disease Module Identification DREAM Challenge', an open competition to comprehensively

84 traZeneca-Sanger Drug Combination Prediction DREAM Challenge, which is a unique platform to unbiasedl

85 rall survival and were evaluated through the DREAM challenge.

86 t represented by the methods used in the HPN-DREAM challenge.

87 A patients was performed in the context of a DREAM Challenge.

88 ing compared to the top models in the ENCODE-DREAM challenge.

89 the ENCODE Project Consortium for the ENCODE-DREAM Challenge.

90 s, such as the ICGC Pilots, CPTAC, ICGC-TCGA DREAM Challenges, and the 1000 Genomes SV Project.

91 histology demonstrate that in the absence of DREAM, chondrocytes fail to arrest proliferation.

92 A long-term dream comes true: An acyclic, neutrally charged silanone

93 t expressing Lin37 proliferate normally, but DREAM completely loses its ability to repress genes in G

94 The Retinoblastoma protein (RB) and DREAM complex (DP, RB-like, E2F4 and MuvB) cooperate to

95 -mediated destruction thereby disrupting the DREAM complex and can prevent exit from the cell cycle i

96 the specificity for p107/p130 over Rb in the DREAM complex and how the complex is disrupted by viral

97 Targeting the DREAM complex and imatinib-induced quiescence could prov

98 d mouse model that is uniquely deficient for DREAM complex assembly.

99 oinformatic analysis is based on genome-wide DREAM complex binding data, p53-depedent mRNA expression

100 tion of CDK4 activity by palbociclib blocked DREAM complex disassembly during cell cycle entry.

101 Our results indicate that the DREAM complex facilitates high gene body HTZ-1/H2A.Z, wh

102 Interfering with DREAM complex formation either by siRNA-mediated knockdo

103 inhibition was dependent on RB and an intact DREAM complex in both normal cells as well as in palboci

104 ow that overexpression of B-Myb disrupts the DREAM complex in human cells, and this activity depends

105 The DREAM complex represses cell cycle genes during quiescen

106 b-like protein p130 and E2F4-DP1 to form the DREAM complex that mediates global repression of cell cy

107 DKN1A) and the recruitment of the repressive DREAM complex to the A3B gene promoter, such that loss o

108 IN54 DNA-binding components of the mammalian DREAM complex, are expressed in a cell cycle-dependent m

109 s p107 and p130, which are components of the DREAM complex, had been suggested to be responsible for

110 er 600 gene products that are targets of the DREAM complex, which is a transcription factor complex t

111 nvolve loss of the repressor function of the DREAM complex, which results in cell-cycle activation; o

112 ere also identified as CC genes bound by the DREAM complex.

113 genes repressed by quiescence-promoting E2F4/DREAM complex.

114 DREAM complexes have been identified in worm, fly, and m

115 the possibility of the existence of multiple DREAM complexes in plants.

116 dREAM complexes represent the predominant form of E2F/RB

117 ogation of DREAM function by knockout of the DREAM component LIN37 results in a reduced repression of

118 DREAM contains an E2F, a retinoblastoma (RB)-family prot

119 Recently, cortical correlates of specific dream contents have been reported, such as the activatio

120 r, the causal mechanisms underlying specific dream contents remain largely elusive.

121 ty in these regions correlated with specific dream contents.

122 These results indicate that DREAM cooperates with RB in repressing E2F-dependent gen

123 -relieving effects, even Morpheus the god of dreams could not have dreamt that his opium tincture wou

124 studies were identified from nine of the ten DREAMS countries; no eligible studies from Lesotho were

125 The protein DREAM decreases development of L-DOPA-induced dyskinesia

126 DREAM-deficient mice displayed persistent and unchecked

127 DREAM-deficient mice show defects in endochondral bone f

128 We found that DREAM deletion does not alter the ultrastructural featur

129 ow that p130 and p107 are not sufficient for DREAM-dependent repression.

130 ers, we designed an open-data, crowdsourced, DREAM (Dialogue for Reverse Engineering Assessments and

131 re we report an alternative approach, deemed DREAMing (Discrimination of Rare EpiAlleles by Melt), wh

132 an biological networks derived from the 2016 DREAM disease module identification challenge as well as

133 in patients with SEA previously enrolled in DREAM (Dose Ranging Efficacy And Safety With Mepolizumab

134 DREAM downregulation was observed early after birth and

135 llular proliferation by interacting with the DREAM (DP, RB-like, E2F and MuvB) complex at two distinc

136 The RB-related protein p130 forms the DREAM (DP, RB-like, E2F, and MuvB) complex and contribut

137 The DREAM (DP, Retinoblastoma [Rb]-like, E2F, and MuvB) comp

138 ents of the multiprotein complexes, known as DREAM/dREAM in human and flies.

139 rmance of random forest based methods in NCI-DREAM drug sensitivity prediction challenge.

140 In this manuscript we consider the NCI-DREAM Drug Synergy Prediction Challenge dataset to ident

141 The occurrence of dreaming during rapid eye movement (REM) sleep prompts i

142 When dreaming during rapid eye movement (REM) sleep, we can p

143 E2F promoters by repressive PRC1.6/E2F6 and DREAM/E2F4 complexes.

144 e know little about the neural correlates of dream emotions.

145 tion regulation in wakefulness-is related to dream emotions.

146 The dream enactment of rapid eye movement sleep behavior dis

147 ye movement sleep motor activity, leading to dream enactment.

148 RBD was diagnosed by reported dream-enactment symptoms or polysomnography.

149 is consistent with a causal contribution to dream experience and has broader implications for unders

150 In both NREM and REM sleep, reports of dream experience were associated with local decreases in

151 dividual reported dreaming or the absence of dream experiences during NREM sleep, suggesting that it

152 een memories during rapid eye movement [REM] dreams followed by indexation and network junction insta

153 site-specific DNA mutation is the long-term dream for cotton breeding scientists.

154 e to variations in brain structure is an old dream for psychology and a crucial question for cognitiv

155 What, then, is consciousness in a dream for?

156 mine from early junior high school, where my dreams for adventure were shaped by Arthur Conan Doyle's

157 their total structures have long been major dreams for nanochemists.

158 pite being roused a similar number of times, dream frequency was reduced in the patients compared to

159 tand the biochemical mechanisms underpinning DREAM function and regulation, we investigated the struc

160 We show that abrogation of DREAM function by knockout of the DREAM component LIN37

161 uvB protein Lin37 as an essential factor for DREAM function.

162 udy MuvB have generated limited insight into DREAM function.

163 These findings suggest that dREAM functions in the organization of transcriptional d

164 activation of the sensorimotor cortex during dreamed hand clenching.

165 In the R6/2 mouse HD model, induced DREAM haplodeficiency or blockade of DREAM activity by c

166 Mostly on these grounds, lucid dreaming has been associated with metacognition.

167 Traditionally, dreaming has been identified with rapid eye-movement (RE

168 DREAM-HF is an example of an ongoing contemporary events

169 The objective of DREAM-HF is to confirm earlier phase 2 results and evalu

170 The DREAM-HF trial (Double-Blind Randomized Assessment of Cl

171 The DREAM-HF trial also presents an alternative approach to

172 to provide lessons learned from the ongoing DREAM-HF trial that relate to biologic plausibility and

173 In a dream, how do contents get into the conscious field?

174 s, such as system justification and American Dream ideology, in engendering Americans' relative insen

175 -/-)) were used to define the involvement of DREAM in dyskinesias.

176 specific roles for RB, p130-DREAM, and p107-DREAM in p53 and p21 mediated repression of cell cycle g

177 further indicated the importance of platelet DREAM in thrombogenesis.

178 our first place solution to the 2017 ENCODE-DREAM in vivo TF binding site prediction challenge.

179 y, we contrasted the presence and absence of dreaming in NREM and REM sleep.

180 The presence of dreams in human sleep, especially in REM sleep, and the

181 Here we report a new approach, called DREAM-in-CDM (Drug Repurposing Effort Applying Integrate

182 The DREAM-in-CDM approach consists of three steps: computati

183 We anticipate that the DREAM-in-CDM approach will be used to repurpose FDA-appr

184 By using the DREAM-in-CDM approach, lapatinib has been identified as

185 events than did the nicotine patch for vivid dreams, insomnia, nausea, constipation, sleepiness, and

186 ange of novel functionalities and to convert dreams into reality.

187 Zambia, and Zimbabwe) that were selected for DREAMS investment in 2015.

188 nsights from the structure, we addressed how DREAM is disassembled upon cell cycle entry.

189 However, it is unknown whether DREAM is expressed in anucleate platelets and plays a ro

190 This dream is generally pursued by following either a top-dow

191 an megakaryoblastic MEG-01 cells showed that DREAM is important for A23187-induced Ca(2+) mobilizatio

192 ecific inhibitors, we observed that platelet DREAM is important for alpha-granule secretion, Ca(2+) m

193 A lasting dream is to elucidate the side-chain-dependent driving f

194 Lucid dreaming is a state of awareness that one is dreaming, w

195 wild-type (WT) control and nonhematopoietic DREAM knockout (KO) mice, DREAM KO control and hematopoi

196 t-active DREAM transgenic mice (daDREAM) and DREAM knockout mice (DREAM(-/-)) were used to define the

197 d nonhematopoietic DREAM knockout (KO) mice, DREAM KO control and hematopoietic DREAM KO mice showed

198 Tail bleeding time was prolonged in DREAM KO control mice, but not in WT or DREAM bone marro

199 KO) mice, DREAM KO control and hematopoietic DREAM KO mice showed a significant delay in time to occl

200 lex in C. reinhardtii that may be similar to DREAM-like complexes in other organisms.

201 e split participants based on their reported dream lucidity.

202 st that therapeutic approaches that activate DREAM may be useful to alleviate L-DOPA-induced dyskines

203 Under normal conditions, vivid dream mentation combined with skeletal muscle paralysis

204 t likely mammalian group to experience vivid dream mentation due to the morphophysiological independe

205 The application of techniques revealing dream mentation in humans to other mammals, specifically

206 a better understanding of the possibility of dream mentation in nonhuman mammals.

207 This non-REM dream mentation may be different in the species where no

208 Alternatively, evidence that dream mentation occurs during both non-REM and REM sleep

209 If we take a hard-stance, that dream mentation only occurs during REM sleep, we conclud

210 Here, we explore the potential for dream mentation, in both non-REM and REM sleep across ma

211 ile at sea, have the potential to experience dream mentation.

212 all mammals have the potential to experience dream mentation.

213 may alter their potential to experience REM dream mentation.

214 potentiated the intensity of dyskinesia, and DREAM(-/-) mice exhibited an increase in expression of m

215 ements in most late cell cycle genes binding DREAM, MMB, or FOXM1-MuvB.

216 confidence ranked target gene maps for TP53, DREAM, MMB-FOXM1 and RB-E2F and enables prediction and d

217 The DREAM modifications did not affect the kinetic profile o

218 over the sensorimotor cortex interferes with dream movement during REM sleep, which is consistent wit

219 mulation, significantly decreased reports of dream movement, especially of repetitive actions.

220 or network co-occurred with the reduction of dream movement, revealing a link between central and per

221 iculty sleeping (n = 3 and n = 2), and vivid dreams (n = 3 and n = 2).

222 Here we describe the HPN-DREAM network inference challenge, which focused on lear

223 All dreamed new prospects require the use of suitable substr

224 n, 12% [245 of 2006 participants]), abnormal dreams (nicotine patch, 12% [251 of 2022 participants]),

225 By using intravital microscopy with DREAM-null mice and their bone marrow chimeras, we demon

226 Using DREAM-null platelets and PI3K isoform-specific inhibitor

227 ntinue to increase at a remarkable rate, the dream of a fully comprehensive computational model of a

228 It has long been the dream of biologists to map gene expression at the single

229 device and was widely expected to fulfil the dream of interventional cardiologists of a transient sca

230 ration for materials scientists, fueling the dream of mimicking life-like motion and tasks in untethe

231 other techniques are helping us realize the dream of seeing--in atomic detail--how different parts o

232 er these approaches will help us realize the dream of understanding the biological "glue" that sustai

233 nd molecular characterizations that were not dreamed of a decade ago.

234 are reaching resolutions that could only be dreamed of just a couple of years ago.

235 For decades, scientists have dreamed of preventing vision loss or of restoring the vi

236 se results imply that reviving the "American dream" of high rates of absolute mobility would require

237 We therefore organized the crowd-sourced DREAM Olfaction Prediction Challenge.

238 The impact of DREAM on L-DOPA efficacy was evaluated using the rotarod

239 Here, we analyze the influence of RB and DREAM on p53-induced gene repression and cell-cycle arre

240 ime predicted whether an individual reported dreaming or the absence of dream experiences during NREM

241 and asking them if they had been conscious (dreaming) or not.

242 We identify the genes repressed by the p53-DREAM pathway and describe a set of genes that is downre

243 our algorithm on simulated data and the HPN-DREAM pathway reconstruction challenge, comparing our pe

244 The DREAM-Phil Bowen ALS Prediction Prize4Life challenge als

245 Here, we report results from the DREAM-Phil Bowen ALS Prediction Prize4Life challenge.

246 Biochemical studies revealed that platelet DREAM positively regulates phosphoinositide 3-kinase (PI

247 Conversely, genetic inactivation of DREAM potentiated the intensity of dyskinesia, and DREAM

248 cation through a crowdsourcing approach, the DREAM Prize4Life ALS Stratification Challenge.

249 wo-electron ORR to H(2)O(2), a future green "dream" process for chemical industry, remain poorly unde

250 in breast and ovarian cancers using the 2017 DREAM Proteogenomics Challenge data.

251 nt a winning algorithm in the 2017 NCI-CPTAC DREAM Proteogenomics Challenge for predicting phosphoryl

252 rect catalytic methane functionalization, a "dream reaction", is typically characterized by relativel

253 as more expressed during periods followed by dream recall, whereas microstate 4 was less expressed.

254 These results suggest that platelet DREAM regulates PI3K-Ibeta activity and plays an importa

255 DREAM-related neuroprotection was linked to an interacti

256 inversely correlated with the length of the dream report (i.e., total word count).

257 every REM stage after which they provided a dream report and rated their dream affect.

258 Dream reports show that self-reflection and volitional c

259 However, when DREAM repressive function is compromised during terminal

260 Since DREAM requires DYRK1A (dual-specificity tyrosine phospho

261 te about whether a salient aspect of sleep - dreaming - requires its input.

262 tor processes and movement sensations of the dream self.

263 eneration of vivid perceptual scenery during dreaming.SIGNIFICANCE STATEMENT Fifty years ago, Michel

264 Together, our results identify a role for DREAM silencing in the activation of ATF6 signaling, whi

265 triking and unexpected overlap between dE2F2/dREAM sites and binding sites for the insulator-binding

266 olve these issues, we launched the ICGC-TCGA DREAM Somatic Mutation Calling Challenge, a crowdsourced

267 tions not only in the waking but also in the dreaming state.

268 ation not only in the waking but also in the dreaming state.SIGNIFICANCE STATEMENT We experience emot

269 correlates with global loss of repression of DREAM target genes in breast and ovarian cancer, our fin

270 actors RB, E2F1 and E2F7 bind to a subset of DREAM target genes that function in G1/S of the CC while

271 a repressive role for gene body H2A.Z, many DREAM targets are up-regulated in htz-1/H2A.Z mutants.

272 Here we show that Caenorhabditis elegans DREAM targets have an unusual pattern of high gene body

273 5, the sole p130/Rb-like gene in C. elegans, DREAM targets have reduced gene body HTZ-1/H2A.Z and inc

274 , MYC, MYBL2 (B-Myb) and FOXM1 are among the DREAM targets that are diminished by SmgGDS depletion.

275 Ovarian Cancer Dream Team (Stand Up To Cancer, Ovarian Cancer Research

276 Baldrick's Pediatric Dream Team Translational Research Grant (SU2C-AACR-DT111

277 d Alliance-National Ovarian Cancer Coalition Dream Team Translational Research Grant, and V Foundatio

278 Thus, Lin37 is an essential component of DREAM that cooperates with Rb to induce quiescence.

279 Despite the interest in dreams that may happen during the night, it has remained

280 en Morpheus the god of dreams could not have dreamt that his opium tincture would be both a gift and

281 ompared to control participants, and the few dreams they reported were less episodic-like in nature a

282 ansition of cancer immunotherapy from a pipe dream to an established powerful cancer treatment modali

283 deral government, and industry to bring this dream to fruition.

284 ampal integrity may be necessary for typical dreaming to occur, and aligns dreaming with other hippoc

285 teins bind to E2F factors forming RB-E2F and DREAM transcriptional repressor complexes.

286 Dominant-active DREAM transgenic mice (daDREAM) and DREAM knockout mice

287 eas after ketamine they reported long, vivid dreams unrelated to the external environment.

288 iveness, but subjects often report "ketamine dreams" upon emergence from anesthesia.

289 ng awakenings with recalled vs. no recall of dreams using the EEG microstate approach.

290 To test the specific contributions of RB and DREAM, we generated RB and p130 knockout cells in primar

291 ng understanding of the neural correlates of dreaming, we know little about the neural correlates of

292 ng understanding of the neural correlates of dreaming, we know little about the neural correlates of

293 , higher percent weight loss needed to reach dream weight, lower physical and mental health status, a

294 enic mice (daDREAM) and DREAM knockout mice (DREAM(-/-)) were used to define the involvement of DREAM

295 o people sometimes report that they remember dreams, while at other times they recall no experience?

296 ry for typical dreaming to occur, and aligns dreaming with other hippocampal-dependent processes such

297 The latter may account for the occurrence of dreaming with rich perceptual content, while the former

298 dreaming is a state of awareness that one is dreaming, without leaving the sleep state.

299 ng sleep appears to suppress the contents of dreaming, yet activation of frontal cortex appears neces

300 al data via the Bayesian optimization method DREAM(ZS).